Five Mistakes That Turn an FDA Inspection Into a Warning Letter
Having helped multiple companies remediate their way out of FDA Warning Letters and 483 observations, I can tell you the underlying mistakes are remarkably consistent. They are also avoidable. Here are five that show up again and again.
1. Treating risk management as a document, not a process. A risk file that exists for the binder, not for decisions, is the first thing an inspector pulls apart. Risk management under ISO 14971 should drive real choices — design changes, controls, accept/reject calls — with the rationale traceable end to end. If your FMEAs were written once and never revisited, that is a finding waiting to happen.
2. Letting traceability break between design inputs and outputs. When you cannot trace a requirement to a design output to a verification result, you cannot prove the device does what you say it does. Broken traceability is one of the most common roots of an inspectional observation — and one of the most expensive to fix after the fact.
3. Ignoring the link between post-market data and design. Complaints, CAPAs, and post-market data are not a separate world from design. The strongest quality systems feed field data back into risk assessments and design changes. The weakest ones let post-market signals sit until they become a recall under 21 CFR Part 806.
4. Rolling out a process without training the people who run it. A new procedure only works if the people doing the work understand it. Remediations fail when the process is fixed on paper but never truly transferred to the engineers and scientists who run it. Sustainable compliance requires training, mentoring, and often certifying the specialists who will own it after the consultants leave.
5. Confusing more paperwork with more compliance. Sixty products do not need sixty repetitive risk management plans. Over-documentation creates its own failure mode: more records to keep current, more chances to fall out of sync, more cost at every update. A single well-structured plan covering a product family is both leaner and easier to defend.
Figure 1 — Quality as a closed loop of traceable decisions and where a broken link becomes a finding.
The common thread is that compliance is not a pile of documents — it is a system of connected decisions you can explain. Build it that way and an inspection becomes a chance to demonstrate control. Build it as a paper exercise and you are one audit away from a Warning Letter.
Which of these have you seen bite a team you have worked with?
LET’S TALK Facing a 483, a Warning Letter, or just want to make sure you never see one? MEDEVEX has guided companies through remediation and back to competitive compliance. Let’s connect.